Corporate Investments and Growth
Apple’s $600 billion US investment over 4 years faces skepticism due to its existing $55 billion annual investment in China, where 90% of its products are manufactured.
Palantir’s quarterly sales reached $1 billion, growing 47% with $306 million in commercial revenue and $426 million from US government contracts, primarily defense and CIA.
AMD’s AI data center GPU revenue disappointed investors, failing to catch up to Nvidia and lacking clarity on resuming sales in China, resulting in a 5% stock decline.
Vertex Pharmaceuticals’ decision to discontinue its pain management drug development significantly impacted future prospects, highlighting the critical importance of drug pipelines in pharma and biotech valuations.